Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis

NCT04057898 is registered in ClinicalTrials.gov with MediciNova as lead sponsor.

NCT NCT04057898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04057898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Lead sponsor
MediciNova
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
May 28, 2020
Completion date
April 30, 2028
Enrollment
234 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis